Replies to post #619762 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I suspect you are right. That said, the Flaskworks optimization and equivalency pathway may be moving closer to catching up to RA approvals. But I definitely agree that they are not waiting on Flaskworks.

[Horseb4CarT]

I’m pretty sure nwbo previously mentioned getting to approval and then demonstrating the FlaskWorks automation/closed system produces the same vaccine.

It’s possible the more automated production process is catching or caught up but logically I would think you wouldn’t complicate or unnecessarily risk first approval.

That establishes an approved baseline process and vaccine and the automated production can be compared against it while not further delaying availability to patients.

[flipper44]

Yes, that’s my take too, but I just don’t know why they need to be so ambiguous about it in the 10q.

Perhaps it’s to assure regulators manufacturing costs WILL go down. Perhaps it’s to help demonstrate why interim reimbursement for the artisan method is legitimate in the intervening time between approval and pending closed automation.